[go: up one dir, main page]

WO2005007150A3 - Method for inhibiting protein synthesis in sperm - Google Patents

Method for inhibiting protein synthesis in sperm Download PDF

Info

Publication number
WO2005007150A3
WO2005007150A3 PCT/IL2004/000648 IL2004000648W WO2005007150A3 WO 2005007150 A3 WO2005007150 A3 WO 2005007150A3 IL 2004000648 W IL2004000648 W IL 2004000648W WO 2005007150 A3 WO2005007150 A3 WO 2005007150A3
Authority
WO
WIPO (PCT)
Prior art keywords
sperm
mrna
inhibiting
substance
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2004/000648
Other languages
French (fr)
Other versions
WO2005007150A2 (en
Inventor
Haim Breitbart
Yael Gur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bar Ilan University
Original Assignee
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bar Ilan University filed Critical Bar Ilan University
Publication of WO2005007150A2 publication Critical patent/WO2005007150A2/en
Publication of WO2005007150A3 publication Critical patent/WO2005007150A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method and pharmaceutical composition for inhibiting translation in sperm cells during capacitation. The pharmaceutical composition comprises a substance that is an inhibitor of translation by 55S, 70S-like, or mitochondrial ribosomes. The substance may be, for example, D-Chloramphenicol, gentamycin, or tetracycline. The substance may also be a polynucleotide that is antisense to a sperm mRNA that is transcribed by 55S, 70S-like, or mitochondrial ribosomes, or a ribonucleozyme that cleaves a sperm mRNA that is transcribed by 55S, 70S-like, or mitochondrial ribosomes. Such an mRNA may be, for example, a sperm mRNA encoding for AT1-R, PKC , Progesterone receptor, Catsper1 or Na-K ATPase 4. The method of the invention comprises administering to sperm cells the pharmaceutical composition of the invention. The method may be used for inhibiting capacitation in sperm cells or for inhibiting a capacitation dependent process in sperm cells such as acrosome reaction, motility, oocyte penetration, in vitro fertilization or in vivo fertilization.
PCT/IL2004/000648 2003-07-17 2004-07-18 Method for inhibiting protein synthesis in sperm Ceased WO2005007150A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48760603P 2003-07-17 2003-07-17
US60/487,606 2003-07-17

Publications (2)

Publication Number Publication Date
WO2005007150A2 WO2005007150A2 (en) 2005-01-27
WO2005007150A3 true WO2005007150A3 (en) 2005-08-04

Family

ID=34079385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/000648 Ceased WO2005007150A2 (en) 2003-07-17 2004-07-18 Method for inhibiting protein synthesis in sperm

Country Status (1)

Country Link
WO (1) WO2005007150A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US11273167B2 (en) 2015-08-03 2022-03-15 The Regents Of The University Of California Compositions and methods for modulating ABHD2 activity
JOP20190100A1 (en) 2016-11-19 2019-05-01 Potenza Therapeutics Inc Anti-gitr antigen-binding proteins and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976893A (en) * 1994-06-02 1999-11-02 Mount Sinai Hospital Methods for identifying binding partners, agonists, and antagonist of a serine/threonine tyrosine kinase
WO2001066084A2 (en) * 2000-03-07 2001-09-13 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
US20020164368A1 (en) * 2000-12-18 2002-11-07 Ronald Zimmerman Male contraceptive method and composition
WO2002090567A2 (en) * 2001-05-03 2002-11-14 Children's Medical Center, Corporation Sperm-specific cation channel, and uses therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976893A (en) * 1994-06-02 1999-11-02 Mount Sinai Hospital Methods for identifying binding partners, agonists, and antagonist of a serine/threonine tyrosine kinase
WO2001066084A2 (en) * 2000-03-07 2001-09-13 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
US20020164368A1 (en) * 2000-12-18 2002-11-07 Ronald Zimmerman Male contraceptive method and composition
WO2002090567A2 (en) * 2001-05-03 2002-11-14 Children's Medical Center, Corporation Sperm-specific cation channel, and uses therefor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRAGG P W ET AL: "PROTEIN SYNTHESIS IN MOUSE SPERMATOZOA", BIOLOGY OF REPRODUCTION, vol. 20, no. 2, 1979, pages 333 - 337, XP008038706, ISSN: 0006-3363 *
DOKOV V K ET AL: "[Arrest of spermatogenesis by various antibiotics: preliminary experimental results]", ACTA UROLOGICA BELGICA. JUL 1970, vol. 38, no. 3, July 1970 (1970-07-01), pages 277 - 287, XP008038737, ISSN: 0001-7183 *
GUR YAEL ET AL: "Protein translation in mammalian sperm.", BIOLOGY OF REPRODUCTION, vol. 68, no. Supplement 1, 2003, & THIRTY-SIXTH ANNUAL MEETING OF THE SOCIETY FOR THE STUDY OF REPRODUCTION; CINCINNATI, OH, USA; JULY 19-22, 2003, pages 295, XP008038696, ISSN: 0006-3363 *
HUWE PETRA ET AL: "Influence of antibiotics on sperm motility: An in vitro experiment", EUROPEAN UROLOGY, vol. 39, no. Suppl. 5, March 2001 (2001-03-01), & XVITH CONGRESS OF THE EUROPEAN ASSOCIATION OF UROLOGY; GENEVA, SWITZERLAND; APRIL 07-10, 2001, pages 132, XP008038694, ISSN: 0302-2838 *
SCHILL W B: "Problems of anticonception in the male. I. Physiologic basis; mechanical and pharmacologic methods", FORTSCHRITTE DER MEDIZIN 1978 GERMANY, vol. 96, no. 29, 1978, pages 1447 - 1451, XP008038757 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Also Published As

Publication number Publication date
WO2005007150A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
Dufau et al. Corticotropin‐releasing factor: an antireproductive hormone of the testis
BRPI0410731A (en) compound, pharmaceutical composition, methods for agonizing the mc4 receptor, treating obesity, treating diabetes mellitus and treating male and / or female sexual dysfunction in a mammal, and, using a compound
BR0312975A (en) Crystalline form of ß2 adrenergic receptor agonist
GEP20074197B (en) 5ht2c receptor modulators
AP1542A (en) Glucocorticoid receptor modulators.
GEP20053710B (en) Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
WO2007084868A2 (en) Treatment of disorders by activation of the unfolded protein response
AP1709A (en) Ethanolate of azithromycin, process for manufacure, and pharmaceutical compositions thereof.
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BR9903380A (en) Process for the hydrogenation of a nitroaromatic composition by contacting the nitroaromatic composition with hydrogen in a reactor that employs a monolith catalyst
BR0115957A (en) Process for the production of 6-aminocaproic acid
PT1254146E (en) CLARITROMYCINE POLYMER PREPARATION PROCESSES AND NEW POLYMORPH IV
PT1828297E (en) Preparation and treatment of bituminous compositions
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
BRPI0411661A (en) n-phenylpiperazine derivatives and methods of prophylaxis or treatment of 5ht 2c receptor-associated diseases
UA86024C2 (en) Tricyclic delta opioid modulators
TW200716134A (en) Tricyclic opioid modulators
WO2005007150A3 (en) Method for inhibiting protein synthesis in sperm
AR008621A1 (en) A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION
PT1213974E (en) DIRECTLY COMPRESSIVE BRIGHT SUBSTANCE FOR TABLETS
ES2178209T3 (en) PROCEDURE TO PREPARE AN ASPHALT COMPOSITION.
WO2004078103A3 (en) G-lactam derivatives as prostaglandin agonists
WO2006096405A8 (en) Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues
Zhi et al. 5-Alkyl 1, 2-dihydrochromeno [3, 4-f] quinolines: a novel class of nonsteroidal progesterone receptor modulators
MX2007007627A (en) Tricyclic o-opioid modulators.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase